Natalia Reyes-Vallejo

Ms. Natalia Reyes-Vallejo

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2022 in Medicinal Chemistry Research
Verified
Journal Article
Closed access
PDF file
EAErik Andrade-Jorge
Erik Andrade-Jorge
FRFernando Rivera-Sánchez
Fernando Rivera-Sánchez
JRJessica E. Rodríguez
Jessica E. Rodríguez
JLJesús A. Lagos-Cruz
Jesús A. Lagos-Cruz
Natalia Reyes-VallejoNatalia Reyes-Vallejo
Natalia Reyes-Vallejo
ARAdelfo Reyes-Ramírez
Adelfo Reyes-Ramírez

9 September 2023 in Medicinal Chemistry Research
Verified
Journal Article
Open access
PDF file
EAErik Andrade-Jorge
Erik Andrade-Jorge
Natalia Reyes-VallejoNatalia Reyes-Vallejo
Natalia Reyes-Vallejo
DCDavid A. Contreras-Cruz
David A. Contreras-Cruz
FRFernando Rivera-Sánchez
Fernando Rivera-Sánchez
JRJessica E. Rodríguez
Jessica E. Rodríguez
ARAdelfo Reyes-Ramírez
Adelfo Reyes-Ramírez
Mental illnesses are one of the most relevant health problems today, among which Alzheimer’s disease (AD) stands out. This is a severe disease that entails different alterations such as chronic cognitive impairment. Commercial therapy drugs have not had the expected success due to their notable and rapid pharmacological efficacy reduction, therefore, we aimed to find new compounds capable of stopping the progression of this disease by cholinesterase inhibition. We synthesized and evaluated nine new racemic compounds (two precursors and their corresponding pyrrolo[2,1-a]isoindol-5-ones with different substituents) derived from phenylglycine as potential acetylcholinesterase inhibitors. Three of them (rac-4, rac-5, and rac-6) showed good enzyme inhibition (Ki 117.5, 90.62, and 77.30 µM, respectively), with a pattern of competitive inhibition type supported by in silico and in vitro experiments, being the rac-6 derivative the best inhibitor. The structural analysis showed that the presence of the ethyl ester group in the structure favors inhibition, likewise, the presence of double bonds increases the affinity of the inhibitor for the enzyme, so these new pyrrolo[2,1-a]isoindol-5-ones derivatives might be helpful for the treatment of Alzheimer’s disease.

20 August 2025 in Molecules
Verified
Journal Article
Open access
PDF file
Natalia Reyes-VallejoNatalia Reyes-Vallejo
Natalia Reyes-Vallejo
Miguel ValdesMiguel Valdes
Miguel Valdes
ARAdelfo Reyes-Ramírez
Adelfo Reyes-Ramírez
JSJUAN ANDRES ALVARADO SALAZAR
JUAN ANDRES ALVARADO SALAZAR
ACAlejandro ------------------- Cruz
Alejandro ------------------- Cruz
JMJessica Elena Mendieta-Wejebe
Jessica Elena Mendieta-Wejebe
Type 2 diabetes is a multifactorial disease characterized by chronic hyperglycemia, insulin resistance, oxidative stress, inflammation, and dyslipidemia, factors that contribute to the development of long-term complications. In this context, the 2-aminobenzothiazole scaffold has emerged as a promising candidate due to its broad spectrum of biological properties. In this study, we performed a multidisciplinary evaluation of benzothiazole derivatives (5a–d, 8a–d, 11a–d, and 12c–d), starting with the in silico prediction of their properties, along with molecular docking against aldose reductase (ALR2) and peroxisome proliferator-activated receptor gamma (PPAR-γ). All compounds complied with the main rules of pharmacological similarity and optimal affinity, highlighting 8d (ΔG = −8.39 kcal/mol for ALR2 and −7.77 kcal/mol for PPAR-γ). Selected compounds from families C and D were synthesized in moderate yields (~60%) and showed low acute oral toxicity (LD50 > 1250 mg/Kg). Compounds 8c and 8d inhibited ALR2 at concentrations below 10 µM. In vivo studies using a streptozotocin-induced diabetic rat model with a high-fat diet revealed that compound 8d produced sustained antihyperglycemic effects and reduced insulin resistance, dyslipidemia, and polydipsia, without inducing hepatotoxicity or displaying intrinsic antioxidant or anti-inflammatory activity. These findings suggest that 8d is a promising candidate for further development in diabetes-related therapeutic strategies.

25 June 2025 in Journal of Molecular Structure
Verified
Journal Article
Open access
Natalia Reyes-VallejoNatalia Reyes-Vallejo
Natalia Reyes-Vallejo
JAJosé A. Altamirano-Espino
José A. Altamirano-Espino
KGKarla I. García-García
Karla I. García-García
FRFernando Rivera-Sánchez
Fernando Rivera-Sánchez
DCDavid Atahualpa Contreras-Cruz
David Atahualpa Contreras-Cruz
ARAdelfo Reyes-Ramírez
Adelfo Reyes-Ramírez

Verified
Journal Article
Open access
PDF file
ABANA MARÍA CORREA BASURTO
ANA MARÍA CORREA BASURTO
Miguel ValdesMiguel Valdes
Miguel Valdes
LPLaura Cristina Cabrera Pérez
Laura Cristina Cabrera Pérez
Natalia Reyes-VallejoNatalia Reyes-Vallejo
Natalia Reyes-Vallejo
ACAlejandro ------------------- Cruz
Alejandro ------------------- Cruz
JMJessica Elena Mendieta-Wejebe
Jessica Elena Mendieta-Wejebe
Type 2 diabetes (T2D) is a multifactorial metabolic disease in which hyperglycemia coexists with insulin resistance, β-cell dysfunction, dyslipidemia, and progressive microvascular and macrovascular complications. The structural versatility of the benzothiazole scaffold has enabled the development of a diverse array of preclinical compounds capable of modulating multiple diabetes-relevant targets. This review critically analyzes the available evidence on benzothiazole-derived compounds exhibiting antidiabetic or other diabetes-related pharmacological activities. No lower publication-date limit was imposed, and the literature included in the review ranged from 1997 to March 2026, encompassing in silico, in vitro, ex vivo, and in vivo evidence. The compounds are discussed according to their primary molecular targets, including α-glucosidase and α-amylase, dipeptidyl peptidase-4 (DPP-4), peroxisome proliferator-activated receptor -γ (PPAR-γ), protein tyrosine phosphatase 1B (PTP1B), glycogen phosphorylase, 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1), aldose reductase, AMPK, and other emerging metabolic targets. Structure–activity relationships (SAR) are highlighted, demonstrating that C-2 functionalization, substitution at the C-5 and C-6 positions, halogenation, the presence of electron-donating or electron-withdrawing groups, and hybridization with thiazolidinedione, rhodanine, triazole, oxadiazole, and other pharmacophores can markedly alter potency, selectivity, and metabolic effects. Various derivatives have matched or outperformed reference agents such as acarbose, glibenclamide, pioglitazone, or aldose reductase inhibitors in preclinical assays. However, a direct comparison between studies is limited by the heterogeneity of models, endpoints, units, and dosing regimens, and clinical efficacy for T2D has not yet been established for this chemical class. Overall, the benzothiazole scaffold emerges not as a universal antidiabetic pharmacophore, but as a highly adaptable platform for the rational design of multitarget compounds.